Drugs / 177Lu-R11228
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07121244 | Oct 2025 → Jun 2026 | hormone receptor-positive breast cancer | Radionetics Oncology | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-R11228 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07121244 ↗ |
| Modality | Small molecule | “177Lu-R11228 is a lutetium-labeled small molecule radioligand” NCT07121244 ↗ |